In vivo, a single intraperitoneal (IP) dose of S1RA at 40 mg/kg leads to a significant reduction in pain responses induced by Allylisothiocyanate (AITC) in wild-type (WT) mice. Further demonstrating its analgesic potential, the same dosing regimen, administered once daily for 11 days starting 3 days before Oxaliplatin injection, effectively counters mechanical and cold hypersensitivity induced by the chemotherapy agent Oxaliplatin in mice^[2].

In cell-based assays, S1RA at a concentration of 100 µM over 4 hours can inhibit intracellular calcium responses in TRPA1-expressing HEK293 cells, illustrating its potential for modulating ion channel activities. It also impairs the formation of TRPA1–Sigma-1R complexes and reduces TRPA1 expression at the plasma membrane, which could underlie some of its therapeutic effects^[2].